Case report: Pallidal deep brain stimulation for treatment of tardive dystonia/dyskinesia secondary to chronic metoclopramide medication.
GPi DBS
case report
metoclopramide
pallidal DBS
tardive dyskinesia
tardive dystonia
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
10
2022
accepted:
19
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Tardive dystonia/dyskinesia (TDD) occurs as a side effect of anti-dopaminergic drugs, including metoclopramide, and is often refractory to medication. While pallidal deep brain stimulation (DBS) has become an accepted treatment for TDD secondary to neuroleptic medication, there is much less knowledge about its effects on metoclopramide-induced TDD. We present the case of a woman with metoclopramide-induced TDD, whose symptoms were initially misjudged as "functional." After 8 years of ineffective medical treatments, she received bilateral implantation of quadripolar electrodes into the posteroventral lateral globus pallidus internus (GPi). GPi DBS led to significant symptom reduction [Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score 24/44 at admission and 7/44 at discharge]. Chronic stimulation led to full recovery from TDD symptoms 9 years after surgery. The BFMDRS motor score decreased to 0.5 (98% improvement). Pallidal DBS may result in sustained improvement of TDD secondary to chronic metoclopramide intake in the long term.
Identifiants
pubmed: 36712453
doi: 10.3389/fneur.2022.1076713
pmc: PMC9877408
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1076713Informations de copyright
Copyright © 2023 Nagel, Ghika, Runge, Wolf and Krauss.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
CNS Spectr. 2022 Apr;27(2):208-217
pubmed: 33213556
J Clin Pharmacol. 2008 Mar;48(3):379-84
pubmed: 18223146
Brain Stimul. 2018 Nov - Dec;11(6):1368-1377
pubmed: 30249417
J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):661-5
pubmed: 15637848
Eur J Neurol. 2011 Jan;18(1):5-18
pubmed: 20482602
Neurogastroenterol Motil. 2019 Nov;31(11):e13617
pubmed: 31050085
Mov Disord. 2010 Jul 30;25(10):1477-81
pubmed: 20629157
J Neurol Sci. 2018 Jun 15;389:55-60
pubmed: 29433807
Neurology. 2009 Jul 7;73(1):53-8
pubmed: 19564584
J Neural Transm (Vienna). 2016 Mar;123(3):231-40
pubmed: 26597125
Nat Clin Pract Gastroenterol Hepatol. 2006 Mar;3(3):138-48
pubmed: 16511548
Nat Rev Neurol. 2019 Mar;15(3):148-160
pubmed: 30683913
Neurotherapeutics. 2020 Oct;17(4):1694-1712
pubmed: 32720245
Parkinsonism Relat Disord. 2013 Feb;19(2):141-7
pubmed: 23099106
Neurology. 2016 Feb 16;86(7):651-9
pubmed: 26791148
Eur J Neurol. 2017 Apr;24(4):552-560
pubmed: 28186378